Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine

Steven J. Lobritto, Philip Rosenthal, Rene Bouw, Mimi Leung, Paul Snell, Richard D. Mamelok – 29 October 2007 – There are few pharmacokinetic data for mycophenolate mofetil (MMF) when used in combination with cyclosporine (CsA) in pediatric liver transplant recipients.

Laparoscopic incisional hernia repair after liver transplantation

Kristin Mekeel, David Mulligan, Kunam Sudhakar Reddy, Adyr Moss, Kristi Harold – 29 October 2007 – Incisional hernias occur in up to 17% of patients after liver transplantation. Laparoscopic ventral hernia repair is associated with fewer wound complications and a decreased incidence of recurrence when compared to open hernia repair in nontransplant patients. This is a retrospective review of 13 patients who underwent laparoscopic incisional hernia repair (LAP group) after liver transplantation compared to 14 patients who had open repairs (OP group; all but one with mesh).

Hepatic pseudotumor in long‐standing biliary atresia patients undergoing liver transplantation

Yueh‐Wei Liu, Allan M. Concejero, Chao‐Long Chen, Yu‐Fan Cheng, Hock‐Liew Eng, Tung‐Liang Huang, Tai‐Yi Chen, Chih‐Chi Wang, Shih‐Ho Wang, Chih‐Che Lin, Chee‐Chien Yong, Chin‐Hsiang Yang, Amornetta P. Jordan, Bruno Jawan – 29 October 2007 – A pseudotumor, giant regenerative nodule, or macroregenerative nodule is an unusual benign hepatic lesion in biliary atresia (BA) patients. This tumor may mimic malignant transformation and may preclude liver transplantation (LT).

Anti‐erythropoietin antibody–mediated pure red cell aplasia in a living donor liver transplant recipient treated for hepatitis C virus

Jordan M. Schecter, J. Gregory Mears, Bachir Alobeid, Paul J. Gaglio – 29 October 2007 – After liver transplantation, reinfection of the newly engrafted liver with hepatitis C virus is essentially universal in patients who are viremic at the time of transplantation. Treatment with interferon preparations with or without ribavirin is recommended in patients with marked histologic injury; however, hematologic toxicity associated with therapy has been reported, which is usually treated with growth factor support, including erythropoietin analogues.

Recurrent hepatic lymphangiomatosis after orthotopic liver transplantation

Seong H. Ra, Robert F. Bradley, Michael C. Fishbein, Ronald W. Busuttil, David S.K. Lu, Charles R. Lassman – 29 October 2007 – Hepatic lymphangiomatosis is a rare disease characterized by an abnormal lymphatic proliferation involving the liver alone, liver and spleen, or multiple organs. Hepatic lymphangiomatosis becomes symptomatic secondary to compression or replacement of the normal parenchyma, which can lead to liver failure. Resection and orthotopic liver transplantation (OLT) can be used as treatment for this disease.

Subscribe to